Sign In/ Sign Up
FDA approves Merck's lung cancer drug as first-line treatment
Oct 25, 2016
The drug has been approved for treating metastatic non-small cell lung cancer (NSCLC) patients with high-levels of a protein known for suppressing the immune system called PD-L1.
Keytruda works by taking the brakes off the immune system by blocking the interaction between PD-L1 and another protein, PD-1. The drug has already been approved for patients who have undergone previous chemotherapy for advanced non-small lung cancer...
U.S. FDA approves Merck's lung cancer drug as first-line treatment - ET HealthWorld
Monday's announcement gives Merck the only approved first-line treatment for lung cancer, one of the biggest markets for cancer drugs. Rival Bristol-M..
4 others like